ClinicalTrials.gg
Not yet recruitingNCT07349589Updated Jan 20, 2026

Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers

A Phase 1 interventional study of DW5524 and DW5524-A in Healthy Adult, sponsored by Daewon Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5524 in healthy adult volunteers.

02

Conditions studied

  • Healthy Adult
03

In context

Lead sponsor

Daewon Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged 19 years or older at the time of screening
  • Individuals weighing 50.0 kg or more and having a (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening

Exclusion criteria

Exclusion Criteria:

  • Those with a current or past medical history of liver, kidney, nervous, mental, respiratory, endocrine, blood disease, tumor, genitourinary, cardiovascular, digestive, or musculoskeletal diseases.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Group1

    Group1

    Drug: DW5524

  • Experimental
    Group2

    Group2

    Drug: DW5524

  • Experimental
    Group3

    Group3

    Drug: DW5524

  • Experimental
    Group4

    Group4

    Drug: DW5524-A

Interventions

  • DrugDW5524

    DW5524

  • DrugDW5524-A

    DW5524-A

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Pharmacodynamic DW5524

    Time frame: up to 8 hour

  2. Cmax

    Pharmacodynamic DW5524

    Time frame: up to 8 hour

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Feb 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 20, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Feb 28, 2026
CompletionEst.
Dec 1, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07349589
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Feb 28, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jan 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion